Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q1 2022 call → NOWe need to determine if management conveys that the business is currently outgrowing the company's own size, i.e., that current activity/demand/commitments are large relative to the smallness of the company. Look for statements about disproportionate scale, e.g., new distribution, new customers, volumes, etc., that are large compared to current revenue or footprint. In the transcript, management discusses growth, new distribution, new products, pricing actions, etc. They mention "Zevia continued scaling through increased velocity, new distribution, introduction of innovation items, and channel expansion." They talk about 24% growth, 21% volume growth, etc. They mention new distribution in mass, club, etc. They mention "13,000 new points of distribution" in April. They mention "3,500 mass merchandiser stores have yet to sell Zevia." They talk about new products, new pack sizes, etc. But does management explicitly convey that the current activity is disproportionately large relative to the company's small size? They do mention that they are a small company? They don't explicitly say "we are small" but they talk about growth rates and expansion. They mention "Zevia is less expensive than 65% of those beverage options" etc. They talk about "we are focused on continuing to bring new households to the Zevia brand while improving unit economics." They mention "our brand continues to grow at 2.4x out of CSD" etc. The key is whether management conveys that the current business is arriving at a scale that is large relative to the company's size. For example, they mention "13,000 new points of distribution" which is a significant expansion. They also mention "3,500 mass merchandiser stores have yet to sell Zevia" implying that the current footprint is small relative to potential. But is that "currently arriving" or is it prospective? They say "We await fall resets to open new opportunities there" so that's future. But they also say "Results from these step changes in the mass channel will be forthcoming in Q2" so that's current. They also mention "In the first quarter, the food channel accounted for more than 40% of total Zevia growth." They talk about new distribution, new products, etc.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.